Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Danesh Alam

Psychiatry Winfield, IL Medical Doctor

NPI 1043227200 CMS profile 1133215

27W350 High Lake Rd Ste 208, Winfield, IL 60190

Open in the dashboard

General payments

$37,582

41 records reported · program years 2019–2025

Research payments

$3,575

Paid to them · 20 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,615,609 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Danesh Alam of Winfield, IL is reported in the CMS Open Payments database as having received $37,582 across 41 general payments and $3,575 in research payments paid to them. Separately, studies naming them as principal investigator received $2,615,609 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,767 5
2025 Research $2,292 12
2024 General $1,069 8
2020 General $2,250 4
2019 General $17,496 24
2019 Research $1,283 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danesh Alam
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Danesh Alam were reported at $16,767. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Danesh Alam Psychiatry median Middle half National median
2019 $17,496 $184 $59–$605 $163
2020 $2,250 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $1,069 $179 $57–$673 $164
2025 $16,767 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $13,111 20 payments
  2. Eli Lilly and Company $11,219 1 payment
  3. Alkermes, Inc. $7,500 1 payment
  4. US WorldMeds, LLC $5,145 11 payments
  5. LivaNova USA, Inc. $500 4 payments
  6. E.R. Squibb & Sons, L.L.C. $51 2 payments
  7. Indivior Inc. $37 1 payment
  8. Otsuka America Pharmaceutical, Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $33,409 7 payments
  2. Travel and Lodging $2,817 9 payments
  3. Food and Beverage $1,355 25 payments
Products named General payments · program years 2019–2025
  1. SPRAVATO $13,111 20 payments
  2. VIVITROL $7,500 1 payment
  3. Lucemyra/Lofexidine $5,145 11 payments
  4. VNS Therapy $500 4 payments
  5. COBENFY $51 2 payments
  6. SUBLOCADE $37 1 payment
  7. ABILIFY ASIMTUFII $19 1 payment
  8. ABILIFY MAINTENA $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $1,448 8 payments
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,283 8 payments
  3. ACADIA Pharmaceuticals Inc $845 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

50

Median for Psychiatry & Neurology: 100

Drug cost

$3,677

Median for Psychiatry & Neurology: $2,986

Branded share of claims

24%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Suboxone Buprenorphine Hcl/Naloxone Hcl Brand 12 $3,291
Trazodone Hcl Generic 21 $347
Fluoxetine Hcl Generic 17 $39

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPRAVATO
  • Janssen Pharmaceuticals, Inc $1,050
$1,050 — —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $9
$9 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

61 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record